The chief executive of a national gym chain has revealed that the rise of weight-loss medications is driving increased demand across its fitness centres.
Will Orr, who heads the low-cost gym chain, The Gym Group, said the company was "absolutely" observing the impact of GLP-1s as a "tailwind and contributory factor" for its business.